

WEST Search History

[Hide Items](#) [Restore](#) [Clear](#) [Cancel](#)

DATE: Monday, December 12, 2005

Hide? Set Name Query Hit Count

DB=USPT; PLUR=YES; OP=ADJ

<input type="checkbox"/>	L22	L21 and l18	64
<input type="checkbox"/>	L21	l17.ti,ab,clm.	589
<input type="checkbox"/>	L20	l17 with l1 not l15	197
<input type="checkbox"/>	L18	L17 same l1 not l15	636
<input type="checkbox"/>	L17	botulin\$ or tetan\$	6214
<input type="checkbox"/>	L16	L15 not l8	134
<input type="checkbox"/>	L15	l1 with L14	137
<input type="checkbox"/>	L14	clostrid\$ or neurotoxin	7673
<input type="checkbox"/>	L13	L12 same l11 same l7 not l8	5
<input type="checkbox"/>	L12	l4 same (l5 or l6)	18189
<input type="checkbox"/>	L11	l1 same L10	5684
<input type="checkbox"/>	L10	"single chain"	12781
<input type="checkbox"/>	L9	l3 and l8	35
<input type="checkbox"/>	L8	l4 same l5 same l6 same l7	45
<input type="checkbox"/>	L7	cleav\$ or protease or proteinase	109621
<input type="checkbox"/>	L6	endocyt\$6	4460
<input type="checkbox"/>	L5	transport\$	465490
<input type="checkbox"/>	L4	bind\$4	369800
<input type="checkbox"/>	L3	l1 with L2	32386
<input type="checkbox"/>	L2	gene or plasmid or protein	193210
<input type="checkbox"/>	L1	fus\$4 or chimer\$3	264391

END OF SEARCH HISTORY

T1 Identification of a novel locus that regulates expression of toxin genes in ***Clostridium*** perfringens PY 2002

T1 ANSWER 4 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002

T1 ANSWER 9 OF 19 CA COPYRIGHT 2005 ACS on STN

T1 Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002

T1 ANSWER 10 OF 19 CA COPYRIGHT 2005 ACS on STN

T1 Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002

T1 ANSWER 11 OF 19 CA COPYRIGHT 2005 ACS on STN

T1 Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002

T1 ANSWER 12 OF 19 CA COPYRIGHT 2005 ACS on STN

T1 Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002

T1 ANSWER 13 OF 19 CA COPYRIGHT 2005 ACS on STN

T1 Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002

T1 ANSWER 14 OF 19 CA COPYRIGHT 2005 ACS on STN

T1 Genome sequence and analysis of the oral bacterium *Fusobacterium nucleatum* strain ATCC 25586 PY 2002

T1 ANSWER 15 OF 19 CA COPYRIGHT 2005 ACS on STN

T1 Complete genome sequence of ***Clostridium*** perfringens, an anaerobic flesh-eater

L19 ANSWER 8 OF 10 CA COPYRIGHT 2005 ACS on STN

AN 136-156405 CA

T1 Method for structural modifying ***Clostridial*** neurotoxins for altering biological activity or persistence by leucine-based motifs

IN Steward, Lance E.; Fernandez-Salas, Ester; Herrington, Todd M.; Aoki, Kei; Roger

PA Allergan Sales, Inc., USA

SO PCT Int. Appl. 102 pp. CODEN: PIXD2

DT Patent

LA English

FANCI NT 5 PATENT NO. A2002008268

KIND DATE A2 20020131 WO 2001-US23122

APPLICATION NO. 20010720 WO 2002008268

DATE 20030220 W-AE,

AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW, RW, GH, GM, BE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, EF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 6903187 B1

20050607 US 2005-620840 2000721 CA 2416988 AA 20020131 CA 2001-2416988 20010720 EP

1309618 A2 20030514 EP 2001-353115 20010720 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR BR 2001012715 A 20030520 BR 2001-12715 20010720

NZ 523652 A 20050324 NZ 2001-523652 20010720 JP 2005517627 T2 20050616 JP 2002-514172

PRAI US 2000-620840 A 20000721 WO 2001-US23122 W 20010720

AB The invention provides a method for structural modifying botulinum toxin with leucine-based motifs. Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the bio. persistence, such as the bio. half-life and/or a bio. activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular ailments and pain.

T1 Metal ion-affinity peptides and method for purification of recombinant proteins PY 2004

T1 ANSWER 5 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 Genes identified as required for proliferation of *Escherichia coli* and their use in antimicrobial drug discovery PY 2001 2002 2001 2002 2002 2003

T1 Targeted delivery of therapeutic agents for nerve regeneration using heavy chain (hc) from botulinum C1 toxin as a neuron-binding domain PY 2004 2004 2005 2005

T1 ANSWER 6 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 Superantigenic conjugates and receptors specific for lipid-based tumor-associated antigens for treatment of neoplastic disease PY 2003

T1 ANSWER 7 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof PY 1999 2002 1999 1999 2000

T1 ANSWER 8 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 Cobing, DNA sequencing, and expression of the gene encoding ***Clostridium*** thermaeum cellulase CelU, the largest catalytic component of the cellulosome PY 1996

T1 ANSWER 1 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 GPF-SNAP25 fluorescence release assay for detecting botulinum neurotoxin protease activity PY 2005 2003

T1 ANSWER 2 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 Modifying source organisms to improve the efficiency of cell-free protein biosynthesis using cell lysates PY 2005 2005

T1 ANSWER 3 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 Optical biosensors and methods of use thereof PY 2004 2004

L19 ANSWER 4 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 The Wisa and Sot genes involved in the regulation of bone development in the vertebrate embryo and their use in modulating patterning in development PY 2003 2005 2004

T1 ANSWER 5 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 Superantigenic conjugates and receptors specific for lipid-based tumor-associated antigens for treatment of neoplastic disease PY 2003

T1 ANSWER 6 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 Superantigenic conjugates and receptors specific for lipid-based tumor-associated antigens for treatment of neoplastic disease PY 2003

T1 ANSWER 7 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 Method for structural modifying ***Clostridial*** neurotoxins for altering biological activity or persistence by leucine-based motifs PY 2002 2003 2003 2005 2005 2005

T1 ANSWER 8 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 Cobing and nucleotide sequence of the DNA gyrase (gyrA) gene from *Mycoplasma hominis* and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin PY 2000

T1 ANSWER 9 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 Cobing and nucleotide sequence of the DNA gyrase (gyrA) gene from *Mycoplasma hominis* and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin PY 2000

T1 ANSWER 10 OF 10 CA COPYRIGHT 2005 ACS on STN

T1 Methods for concentrating and detecting Igands using magnetic particles PY 1998 1998 2000 2002